| HOME >> BIOLOGY >> TECHNOLOGY |
Research and
development 3,044,225 1,772,371 5,229,981 4,361,474
General and
administrative 806,675 643,191 1,319,236 1,315,266
Stock
compensation 352,264 131,747 494,538 278,186
Amortization of
intellectual
property 110,537 110,537 221,074 221,074
Interest on long
term debt 28,172 1,538 58,700 4,191
-------------------------------------------------------------------------
4,341,872 2,659,384 7,323,528 6,180,191
Interest income 58,634 357,865 159,694 541,186
-------------------------------------------------------------------------
Net and
comprehensive
loss for the
period $ (3,994,800) $ (2,301,519) $ (6,581,110) $ (3,972,769)
Deficit, beginning
of period (35,934,440) (25,385,336) (33,348,130) (23,714,086)
-------------------------------------------------------------------------
Deficit, end
of period $(39,929,240) $(27,686,855) $(39,929,240) $(27,686,855)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net and
comprehensive
loss per common
share
Basic and fully
diluted $ (0.07) $ (0.04) $ (0.12) $ (0.07)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average
number of common
shares outstanding
Basic and fully
diluted 55,623,367 55,441,019 55,571,069 55,441,019
-----------------------------------------------
'/>"/>
| SOURCE GeneNews Limited Copyright©2008 PR Newswire. All rights reserved |